Dermata Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 21, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 21, 2024

DRMA$0.71-7.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Stockholders’ Equity (Deficit)

Additional · Total
Common Stock · Paid-in · Accumulated · Stockholders’
	Shares	Par Value	Capital	Deficit	Equity
Balance at December 31, 2021	520,540	$52	$46,089,327	$(35,982,275)	$10,107,104
Issuance of Common Stock and warrants, net of issuance costs	56,162	6	4,276,359	-	4,276,365
Issuance of Common Stock upon exercise of pre-funded warrants	179,688	18	269	-	287
Issuance of restricted stock unit awards	-	-	166,875	-	166,875
Issuance of Common Stock upon conversion of restricted stock units	13,725	1	(1)	-	-
Stock-based compensation	-	-	1,082,136	-	1,082,136
Net loss	-	-	-	(9,610,913)	(9,610,913)
Balance at December 31, 2022	770,115	$77	$51,614,965	$(45,593,188)	$6,021,854
Issuance of Common Stock and warrants, net of issuance costs	543,555	55	5,651,613	-	5,651,668
Issuance of Common Stock upon exercise of pre-funded warrants	1,875,445	187	-	-	187
Issuance of Common Stock upon exercise of warrants, net of issuance costs	742,095	74	1,953,883	-	1,953,957
Settlement of fractional shares paid in cash	(370)		(40)	-	(40)
Stock-based compensation	-	-	522,082	-	522,082
Net loss	-	-	-	(7,794,690)	(7,794,690)
Balance at December 31, 2023	3,930,840	$393	$59,742,503	$(53,387,878)	$6,355,018

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.